These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 32777746)

  • 1. Targeting CD73 to augment cancer immunotherapy.
    Roh M; Wainwright DA; Wu JD; Wan Y; Zhang B
    Curr Opin Pharmacol; 2020 Aug; 53():66-76. PubMed ID: 32777746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD73 as a potential opportunity for cancer immunotherapy.
    Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the adenosine pathway for cancer immunotherapy.
    Hammami A; Allard D; Allard B; Stagg J
    Semin Immunol; 2019 Apr; 42():101304. PubMed ID: 31604539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
    Allard B; Longhi MS; Robson SC; Stagg J
    Immunol Rev; 2017 Mar; 276(1):121-144. PubMed ID: 28258700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD73: a novel target for cancer immunotherapy.
    Zhang B
    Cancer Res; 2010 Aug; 70(16):6407-11. PubMed ID: 20682793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD73: an emerging checkpoint for cancer immunotherapy.
    Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B
    Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory role of CD39 and CD73 in tumor immunity.
    Kaplinsky N; Williams K; Watkins D; Adams M; Stanbery L; Nemunaitis J
    Future Oncol; 2024; 20(19):1367-1380. PubMed ID: 38652041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
    Baghbani E; Noorolyai S; Shanehbandi D; Mokhtarzadeh A; Aghebati-Maleki L; Shahgoli VK; Brunetti O; Rahmani S; Shadbad MA; Baghbanzadeh A; Silvestris N; Baradaran B
    Life Sci; 2021 Oct; 282():119826. PubMed ID: 34265363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
    Kumar M; Lowery R; Kumar V
    SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the CD73-adenosine axis in immuno-oncology.
    Allard D; Chrobak P; Allard B; Messaoudi N; Stagg J
    Immunol Lett; 2019 Jan; 205():31-39. PubMed ID: 29758241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD73-adenosine: a next-generation target in immuno-oncology.
    Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
    Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of CD73 delays glioblastoma growth by modulating the immune environment.
    Azambuja JH; Schuh RS; Michels LR; Iser IC; Beckenkamp LR; Roliano GG; Lenz GS; Scholl JN; Sévigny J; Wink MR; Stefani MA; Battastini AMO; Figueiró F; Teixeira HF; Braganhol E
    Cancer Immunol Immunother; 2020 Sep; 69(9):1801-1812. PubMed ID: 32350590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
    Tripathi A; Lin E; Xie W; Flaifel A; Steinharter JA; Stern Gatof EN; Bouchard G; Fleischer JH; Martinez-Chanza N; Gray C; Mantia C; Thompson L; Wei XX; Giannakis M; McGregor BA; Choueiri TK; Agarwal N; McDermott DF; Signoretti S; Harshman LC
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
    Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
    J Clin Invest; 2020 Mar; 130(3):1185-1198. PubMed ID: 31770109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
    Figueiró F; de Oliveira CP; Bergamin LS; Rockenbach L; Mendes FB; Jandrey EH; Moritz CE; Pettenuzzo LF; Sévigny J; Guterres SS; Pohlmann AR; Battastini AM
    Purinergic Signal; 2016 Jun; 12(2):303-12. PubMed ID: 26910734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
    Jin D; Fan J; Wang L; Thompson LF; Liu A; Daniel BJ; Shin T; Curiel TJ; Zhang B
    Cancer Res; 2010 Mar; 70(6):2245-55. PubMed ID: 20179192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
    Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
    Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
    [No Abstract]   [Full Text] [Related]  

  • 20. CD73: a potent suppressor of antitumor immune responses.
    Beavis PA; Stagg J; Darcy PK; Smyth MJ
    Trends Immunol; 2012 May; 33(5):231-7. PubMed ID: 22487321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.